GREENLAND MINES LTD Increase (Decrease) in Other Operating Liabilities
GREENLAND MINES LTD (GRML) reported Increase (Decrease) in Other Operating Liabilities of $22.10 thousand for the 3-month period ending 2025-03-31, per its 10-Q/A filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2026-08-14
- GREENLAND MINES LTD increase (decrease) in other operating liabilities for the quarter ending 2025-03-31 was $22.10K.
- GREENLAND MINES LTD increase (decrease) in other operating liabilities for the quarter ending 2024-12-31 was $0.00.
- GREENLAND MINES LTD increase (decrease) in other operating liabilities for the quarter ending 2024-09-30 was $44.96K.
- GREENLAND MINES LTD increase (decrease) in other operating liabilities for fiscal 2024 was $60.02K.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2025-03-31 | $22.10K 10-Q/A · filed 2026-08-14 | $22.10K derived: sum of 2 quarters · filed 2026-08-14 | $67.06K derived: sum of 3 quarters · filed 2026-08-14 | |
| 2024-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-08-14 | $44.96K derived: sum of 2 quarters · filed 2026-08-14 | $60.02K 10-K/A · filed 2026-08-14 | |
| 2024-09-30 | $44.96K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $60.02K 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $15.06K 10-Q · filed 2025-08-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |